Usefulness of contrast-enhanced ultrasonography using Sonazoid for the assessment of therapeutic response to percutaneous radiofrequency ablation for hepatocellular carcinoma

Hepatology Research

Volumn 45, Issue 4, 2015, Pages 432-440

  Nishigaki, Yoichi ^a   Hayashi, Hideki ^a   Tomita, Eiichi ^a   Suzuki, Yusuke ^a   Watanabe, Naoki ^a   Watanabe, Satoshi ^a   Watanabe, Chiaki ^a   Takagi, Yui ^a   Kato, Tomohiro ^a   Naiki, Takafumi ^a  

^a Gifu Municipal Hospital   (Japan)

Author keywords

Contrast enhanced ultrasonography; Hepatocellular carcinoma; Radiofrequency ablation; Sonazoid; Treatment assessment

Indexed keywords

BILIRUBIN; PERFLUBUTANE;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST-ENHANCED ULTRASONOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HEMATOTHORAX; HUMAN; LIVER ABSCESS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERCUTANEOUS TRANSHEPATIC DRAINAGE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; REAL TIME ULTRASOUND SCANNER; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL RATE; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84926211858     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12370     Document Type: Article

References (40)

1. Chen MS, Li JQ, Zheng Y etal. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328.
2. N'Kontchou G, Mahamoudi A, Aout M etal. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50: 1475-1483.
3. Livraghi T, Meloni F, Di Stasi M etal. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice. Hepatology 2008; 47: 82-89.
4. Waki K, Aikata H, Katamura Y etal. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up. J Gastroenterol Hepatol 2010; 25: 597-604.
5. Shiina S, Tateishi R, Arano T etal. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107: 569-577.
6. Salmi A, Turrini R, Lanzani G, Savio A, Anglani L. Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis. Int J Med Sci 2008; 5: 327-332.
7. Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y. Contrast-enhanced sonography-guided radiofrequency ablation for the local recurrence of previously treated hepatocellular carcinoma undetected by B-mode sonography. J Clin Ultrasound 2010; 38: 339-345.
8. Wen YL, Kudo M, Zheng RQ etal. Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003; 181: 57-63.
9. Wen YL, Kudo M, Zheng RQ etal. Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. AJR Am J Roentgenol 2004; 182: 1019-1026.
10. Celli N, Gaiani S, Piscaglia F etal. Characterization of liver lesions by real-time contrast-enhanced ultrasonography. Eur J Gastroenterol Hepatol 2007; 19: 3-14.
11. Minami Y, Kudo M, Chung H etal. Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial. AJR Am J Roentgenol 2007; 188: 489-494.
12. Bartolotta TV, Taibbi A, Midiri M, De Maria M. Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound. Abdom Imaging 2008; 33: 501-511.
13. Kawada N, Ohkawa K, Tanaka S etal. Improved diagnosis of well-differentiated hepatocellular carcinoma with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid-enhanced magnetic resonance imaging and Sonazoid contrast-enhanced ultrasonography. Hepatol Res 2010; 40: 930-936.
14. Hatanaka K, Chung H, Kudo M etal. Usefulness of the post-vascular phase of contrast-enhanced ultrasonography with sonazoid in the evaluation of gross types of hepatocellular carcinoma. Oncology 2010; 78 (Suppl 1): 53-59.
15. Maruyama H, Takahashi M, Ishibashi H, Okabe S, Yoshikawa M, Yokosuka O. Changes in tumor vascularity precede microbubble contrast accumulation deficit in the process of dedifferentiation of hepatocellular carcinoma. Eur J Radiol 2010; 75: e102-106.
16. Mita K, Kim SR, Kudo M etal. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2cm. World J Gastroenterol 2010; 16: 4187-4192.
17. Shiozawa K, Watanabe M, Takayama R etal. Evaluation of local recurrence after treatment for hepatocellular carci noma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography. J Clin Ultrasound 2010; 38: 182-189.
18. Mandai M, Koda M, Matono T etal. Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT. Br J Radiol 2011; 84: 499-507.
19. Sugimoto K, Moriyasu F, Saito K etal. Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading. J Ultrasound Med 2012; 31: 529-538.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
21. Oken MM, Creech RH, Tormey DC etal. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
22. Minami Y, Kudo M, Kawasaki T, Chung H, Ogawa C, Shiozaki H. Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. AJR Am J Roentgenol 2004; 182: 1224-1226.
23. Inoue T, Minami Y, Chung H etal. Radiofrequency ablation for hepatocellular carcinoma: assistant techniques for difficult cases. Oncology 2010; 78 (Suppl 1): 94-101.
24. Song I, Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol 2009; 19: 2630-2640.
25. Ohnishi T, Yasuda I, Nishigaki Y etal. Intraductal chilled saline perfusion to prevent bile duct injury during percutaneous radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23: e410-415.
26. Nakazawa T, Kokubu S, Shibuya A etal. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007; 188: 480-488.
27. Salvaggio G, Campisi A, Lo Greco V, Cannella I, Meloni MF, Caruso G. Evaluation of posttreatment response of hepatocellular carcinoma: comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT. Abdom Imaging 2010; 35: 447-453.
28. Faccioli N, D'Onofrio M, Comai A, Cugini C. Contrast-enhanced ultrasonography in the characterization of benign focal liver lesions: activity-based cost analysis. Radiol Med (Torino) 2007; 112: 810-820.
29. Romanini L, Passamonti M, Aiani L etal. Economic assessment of contrast-enhanced ultrasonography for evaluation of focal liver lesions: a multicentre Italian experience. Eur Radiol 2007; 17 (Suppl 6): F99-106.
30. Piscaglia F, Leoni S, Cabibbo G etal. Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. Dig Liver Dis 2010; 42: 729-734.
31. Sirli R, Sporea I, Martie A, Popescu A, Danila M. Contrast enhanced ultrasound in focal liver lesions-a cost efficiency study. Med Ultrasonogr 2010; 12: 280-285.
32. Tanaka H, Iijima H, Nouso K etal. Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. Hepatol Res 2012; 42: 376-384.
33. Dill-Macky MJ, Asch M, Burns P, Wilson S. Radiofrequency ablation of hepatocellular carcinoma: predicting success using contrast-enhanced sonography. AJR Am J Roentgenol 2006; 186: S287-295.
34. Sparchez Z, Radu P, Anton O, Socaciu M, Badea R. Contrast enhanced ultrasound in assessing therapeutic response in ablative treatments of hepatocellular carcinoma. J Gastrointestin Liver Dis 2009; 18: 243-248.
35. Andreana L, Kudo M, Hatanaka K etal. Contrast-enhanced ultrasound techniques for guiding and assessing response to locoregional treatments for hepatocellular carcinoma. Oncology 2010; 78 (Suppl 1): 68-77.
36. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-451.
37. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232: 381-391.
38. Catalano O, Lobianco R, Esposito M, Siani A. Hepatocellular carcinoma recurrence after percutaneous ablation therapy: helical CT patterns. Abdom Imaging 2001; 26: 375-383.
39. Nishikawa H, Inuzuka T, Takeda H etal. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol 2011; 46: 1418-1426.
40. Luo W, Numata K, Morimoto M etal. Role of Sonazoid-enhanced three-dimensional ultrasonography in the evaluation of percutaneous radiofrequency ablation of hepatocellular carcinoma. Eur J Radiol 2010; 75: 91-97.